Castration-Resistant Prostate Cancer
Castration-resistant prostate cancer (CRPC) is a form of prostate cancer that no longer responds to hormone therapy designed to lower testosterone levels, leading to continued cancer growth.
Castration-Resistant Prostate Cancer: Lutetium [177Lu] VIPIVOTIDE TETRAXETAN
We are studying a new treatment for men with castration-resistant prostate cancer to see how well it works alone and with other medications. The goal is to evaluate its effects on prostate-specific antigen (PSA) levels and overall health.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you 18 years old or older?
- Do you have prostate cancer that has been confirmed by a doctor?
- Are you currently receiving treatment to lower testosterone, like a GnRH agonist or have you had surgery to remove your testicles?
- Have you had any major treatments for prostate cancer, like chemotherapy or certain hormone therapies, in the last 2 years?
- Do you have any serious heart problems or conditions that could cause seizures?
What similar medicines might you know?
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Firmagon
Illuccix
Isoprotrace
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
University Hospital Olomouc
2001: Onkologická klinika
Olomouc, Czechia
Institut De Cancerologie De L Ouest
2105:Oncology
Angers, France
Centre Francois Baclesse
2102; Oncology
Caen, France
Sponsor: Novartis Pharma AG
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.